148 related articles for article (PubMed ID: 30468042)
1. Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction: Results from The Korea Acute Heart Failure (KorAHF) Registry.
Kim SH; Yun SC; Park JJ; Lee SE; Jeon ES; Kim JJ; Cho MC; Chae SC; Kang SM; Choi DJ; Yoo BS; Kim KH; Oh BH; Baek SH;
Korean Circ J; 2019 Mar; 49(3):238-248. PubMed ID: 30468042
[TBL] [Abstract][Full Text] [Related]
2. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
Lund LH; Benson L; Dahlström U; Edner M; Friberg L
JAMA; 2014 Nov; 312(19):2008-18. PubMed ID: 25399276
[TBL] [Abstract][Full Text] [Related]
3. Association Between β-Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry.
Meyer M; Du Fay Lavallaz J; Benson L; Savarese G; Dahlström U; Lund LH
J Card Fail; 2021 Nov; 27(11):1165-1174. PubMed ID: 33971289
[TBL] [Abstract][Full Text] [Related]
4. Impact of heart rate changes during hospitalization on outcome in heart failure with preserved ejection fraction.
Liu D; Cui X; Xu Y; Xu L; Xie Z; Yuan S; Wang P; Wang Y; Qian S; Gong H; Nordbeck P; Yang J; Zhou J; Ge J; Sun A
ESC Heart Fail; 2024 Mar; ():. PubMed ID: 38514992
[TBL] [Abstract][Full Text] [Related]
5. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
Lund LH; Benson L; Dahlström U; Edner M
JAMA; 2012 Nov; 308(20):2108-17. PubMed ID: 23188027
[TBL] [Abstract][Full Text] [Related]
6. Short and long-term prognostic value of hyponatremia in heart failure with preserved ejection fraction versus reduced ejection fraction: An analysis of the Korean Acute Heart Failure registry.
Park JJ; Cho YJ; Oh IY; Park HA; Lee HY; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
Int J Cardiol; 2017 Dec; 248():239-245. PubMed ID: 28821416
[TBL] [Abstract][Full Text] [Related]
7. Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis.
Kaddoura R; Madurasinghe V; Chapra A; Abushanab D; Al-Badriyeh D; Patel A
Curr Probl Cardiol; 2024 Mar; 49(3):102376. PubMed ID: 38184132
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of chronic obstructive pulmonary disease on adverse prognosis in hospitalized heart failure patients with preserved ejection fraction - A report from the JASPER registry.
Sato Y; Yoshihisa A; Oikawa M; Nagai T; Yoshikawa T; Saito Y; Yamamoto K; Takeishi Y; Anzai T
J Cardiol; 2019 Jun; 73(6):459-465. PubMed ID: 30718015
[TBL] [Abstract][Full Text] [Related]
9. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
[TBL] [Abstract][Full Text] [Related]
10. Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry.
Stolfo D; Uijl A; Benson L; Schrage B; Fudim M; Asselbergs FW; Koudstaal S; Sinagra G; Dahlström U; Rosano G; Savarese G
Eur J Heart Fail; 2020 Jan; 22(1):103-112. PubMed ID: 31478583
[TBL] [Abstract][Full Text] [Related]
11. Predictors and Prognostic Value of Worsening Renal Function During Admission in HFpEF Versus HFrEF: Data From the KorAHF (Korean Acute Heart Failure) Registry.
Kang J; Park JJ; Cho YJ; Oh IY; Park HA; Lee SE; Kim MS; Cho HJ; Lee HY; Choi JO; Hwang KK; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
J Am Heart Assoc; 2018 Mar; 7(6):. PubMed ID: 29535141
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Heart Rate and Beta-Blocker Use in Sinus Rhythm in Patients with Heart Failure and Preserved Ejection Fraction.
Li S; Li X
High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):405-411. PubMed ID: 31625118
[TBL] [Abstract][Full Text] [Related]
13. Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study.
Gu J; Fan YQ; Bian L; Zhang HL; Xu ZJ; Zhang Y; Chen QZ; Yin ZF; Xie YS; Wang CQ
Eur J Prev Cardiol; 2016 Sep; 23(13):1421-8. PubMed ID: 26915580
[TBL] [Abstract][Full Text] [Related]
14. Effect of Beta-blocker therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction.
Farasat SM; Bolger DT; Shetty V; Menachery EP; Gerstenblith G; Kasper EK; Najjar SS
Am J Cardiol; 2010 Jan; 105(2):229-34. PubMed ID: 20102924
[TBL] [Abstract][Full Text] [Related]
15. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
[TBL] [Abstract][Full Text] [Related]
16. Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients With Heart Failure.
Lee SE; Lee HY; Cho HJ; Choe WS; Kim H; Choi JO; Jeon ES; Kim MS; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Cho MC; Kim JJ; Oh BH
JACC Heart Fail; 2017 Nov; 5(11):810-819. PubMed ID: 29096790
[TBL] [Abstract][Full Text] [Related]
17. Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction.
Tsujimoto T; Kajio H
Sci Rep; 2018 Jun; 8(1):9556. PubMed ID: 29934526
[TBL] [Abstract][Full Text] [Related]
18. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
Silverman DN; Plante TB; Infeld M; Callas PW; Juraschek SP; Dougherty GB; Meyer M
JAMA Netw Open; 2019 Dec; 2(12):e1916598. PubMed ID: 31800067
[TBL] [Abstract][Full Text] [Related]
19. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
[TBL] [Abstract][Full Text] [Related]
20. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study.
Takada T; Sakata Y; Miyata S; Takahashi J; Nochioka K; Miura M; Tadaki S; Shimokawa H;
Eur J Heart Fail; 2014 Mar; 16(3):309-16. PubMed ID: 24464774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
